Clinical trial
A Phase 2 Multicenter, Open-label Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and Pegylated Interferon Alpha (PEG-IFNα) for the Treatment of Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
NCT06491563 is registered in ClinicalTrials.gov with Brii Biosciences Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Multicenter, Open-label Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and Pegylated Interferon Alpha (PEG-IFNα) for the Treatment of Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
- Lead sponsor
- Brii Biosciences Limited
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- August 6, 2024
- Completion date
- June 30, 2027
- Enrollment
- 150 (estimated)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
for treatment of chronic hepatitis b virus infection